 Asymptomatic men with progressive metastatic CRPC post- treatment with abiraterone acetate pre-chemotherapy for metastatic disease will be treated on a randomized, multi-Institutional open label study to determine if treatment with intramuscular T given on a doseschedule designed to result in rapid cycling from the polar extremes of supraphysiologic to near castrate levels i.e. Bipolar Androgen Therapy BAT will improve primary and secondary objectives vs. enzalutamide as standard therapy. 